The effect of NAFLD on the hepatic PPAR-γ was reversed by camel milk treatment in the NAFLD+CM group which showed greater levels (p < 0.0001) of PPAR-γ proteins in comparison to the NAFLD group. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.